Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

about

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

P2860

Q39093352-89955CBF-6BFD-4210-866D-2D46E3919517

P2860

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

Item

http://www.wikidata.org/entity/Q35799330

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Improving clinical benefit for ...... deprivation and immunotherapy.

@ast

Improving clinical benefit for ...... deprivation and immunotherapy.

@en

type

Item

label

Improving clinical benefit for ...... deprivation and immunotherapy.

@ast

Improving clinical benefit for ...... deprivation and immunotherapy.

@en

prefLabel

Improving clinical benefit for ...... deprivation and immunotherapy.

@ast

Improving clinical benefit for ...... deprivation and immunotherapy.

@en

P1476

Improving clinical benefit for ...... deprivation and immunotherapy

@en

P2093

Anna R Kwilas

http://www.w3.org/2001/XMLSchema#string

Anthony S Malamas

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

Peter S Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors

Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

P304

e1009303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2015.1009303

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sofia R Gameiro

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26155431

http://www.w3.org/2001/XMLSchema#string

P932

4485836

http://www.w3.org/2001/XMLSchema#string

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

about

P2860

P2860

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932